Pfizer Inc. $PFE Position Lessened by Davidson Trust Co.

Davidson Trust Co. decreased its stake in Pfizer Inc. (NYSE:PFE) by 13.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,432 shares of the biopharmaceutical company’s stock after selling 6,172 shares during the period. Davidson Trust Co.’s holdings in Pfizer were worth $980,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Brighton Jones LLC raised its stake in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. GAMMA Investing LLC raised its stake in Pfizer by 69.0% during the 1st quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company’s stock valued at $1,600,000 after acquiring an additional 25,785 shares in the last quarter. Elevation Point Wealth Partners LLC raised its stake in Pfizer by 15.9% during the 1st quarter. Elevation Point Wealth Partners LLC now owns 16,809 shares of the biopharmaceutical company’s stock valued at $426,000 after acquiring an additional 2,311 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its stake in Pfizer by 55.3% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 2,606,123 shares of the biopharmaceutical company’s stock valued at $66,039,000 after acquiring an additional 928,180 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $24.53 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $139.44 billion, a price-to-earnings ratio of 13.05, a PEG ratio of 0.82 and a beta of 0.55. The stock’s fifty day simple moving average is $24.88 and its 200 day simple moving average is $24.12. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.82.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 91.49%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Bank of America lifted their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.